Entrada Therapeutics is a biotechnology business based in the US. Entrada Therapeutics shares (TRDA) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $9.09 – an increase of 1.68% over the previous week. Entrada Therapeutics employs 183 staff and has a trailing 12-month revenue of around $210.8 million.
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $9.09 |
|---|---|
| 52-week range | $7.10 - $21.79 |
| 50-day moving average | $10.08 |
| 200-day moving average | $14.85 |
| Wall St. target price | $24.33 |
| PE ratio | 5.2798 |
| Dividend yield | N/A |
| Earnings per share (TTM) | $1.68 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $9.23 from 2025-05-02
| 1 week (2025-04-28) | 4.06% |
|---|---|
| 1 month (2025-04-04) | 16.25% |
| 3 months (2025-02-06) | -31.53% |
| 6 months (2024-11-06) | -50.54% |
| 1 year (2024-05-06) | -31.63% |
|---|---|
| 2 years (2023-05-05) | -23.84% |
| 3 years (2022-05-05) | 49.11% |
| 5 years (2020-05-02) | N/A |
Valuing Entrada Therapeutics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Entrada Therapeutics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Entrada Therapeutics's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 5x. In other words, Entrada Therapeutics shares trade at around 5x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
However, Entrada Therapeutics's P/E ratio is best considered in relation to those of others within the biotechnology industry or those of similar companies.
Entrada Therapeutics's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $50.8 million.
The EBITDA is a measure of a Entrada Therapeutics's overall financial performance and is widely used to measure a its profitability.
To put Entrada Therapeutics's EBITDA into context you can compare it against that of similar companies.
| Revenue TTM | $210.8 million |
|---|---|
| Gross profit TTM | $85.5 million |
| Return on assets TTM | 5.9% |
| Return on equity TTM | 19.56% |
| Profit margin | 31.14% |
| Book value | $12.04 |
| Market Capitalization | $336.6 million |
TTM: trailing 12 months
We're not expecting Entrada Therapeutics to pay a dividend over the next 12 months.
You may also wish to consider:
Over the last 12 months, Entrada Therapeutics's shares have ranged in value from as little as $7.1 up to $21.79. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Entrada Therapeutics's is 0.034. This would suggest that Entrada Therapeutics's shares are less volatile than average (for this exchange).
To put Entrada Therapeutics's beta into context you can compare it against those of similar companies.
Entrada Therapeutics, Inc. , a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. The company's EEV platform develops products based on oligonucleotide, enzyme, and antibody-conjugated EEV peptides. Its therapeutic candidates, which include ENTR-601-44 that is in Phase 1 clinical trial for the treatment of Duchenne muscular dystrophy; and VX-670, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1. The company also offers ENTR-601-45, ENTR-601-50, and ENTR-601-51, which are in preclinical trial, for the treatment of Duchenne muscular dystrophy; and PTI-501, an intracellular thymidine phosphorylase enzyme replacement therapy for the treatment of mitochondrial neurogastrointestinal encephalomyopathy. It has strategic collaboration and license agreements with Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize VX-670; and Pierrepont Therapeutics, Inc. to advance the development of PTI-501.
Track the progress of the S&P 500 stocks to make more informed investment decisions.
See our picks for the best brokers for trading S&P 500 stocks, ETFs, options and futures.
These are the stocks to buy when you don’t have much to spend.
Explore the best bonuses for opening a new brokerage account.
Compare pros, cons, research tools and reviews for these two trading platforms.
Some of the best trading apps like Robinhood are SoFi, Tastytrade, Public, eToro, Acorns, Interactive Brokers, E*TRADE and more.
Compare pros, cons, research tools and reviews for these two trading platforms.
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .
SoFi Invest is a no-fee commissions platform with both active and automated investment accounts.
Webull is a broker with zero-commission trading and a suite of tools to help you invest.